A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes. - Full Text View

A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.

This study is enrolling participants by invitation only.

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00415428

Purpose

The overall objective is to increase the adherence to national guidelines for patients with established CVD and/or Type 2 diabetes by means of repeated post-graduate educational meetings and regular evaluation of the optimisation initiatives, demonstrated by improvement of goal attainment in general practice.

Condition	Intervention
Heart Diseases Vascular Diseases Diabetes Mellitus, Type 2	Behavioral: Patient adherence to national educational guidelines.

MedlinePlus related topics:

Diabetes Heart Diseases Vascular Diseases

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective

Official Title:	Patient And Physician Alliance -Guideline Education Treatment Optimization

Further study details as provided by Pfizer:

Estimated Enrollment:	4000
Study Start Date:	January 2007

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with known CVD diagnosed ≥ 6 months before inclusion And/Or
Patients with Type 2 diabetes diagnosed ≥ 6 months before inclusion

Exclusion Criteria:

Patients with a life expectancy ≤ 2 years
Patients unable/unwilling to understand/follow instructions
Patients taking part in a clinical study involving an investigational drug
Patients that at the time of inclusion is followed by a specialist for their CVD and/or T2D

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00415428

Locations


Denmark
	Pfizer Investigational Site
	Denmark, Denmark

Sponsors and Collaborators

Pfizer

Investigators


Study Director:	Pfizer CT.gov Call Center	Pfizer

More Information

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

Responsible Party:	Pfizer, Inc. ( Director, Clinical Trial Disclosure Group )
Study ID Numbers:	A2581154
First Received:	December 20, 2006
Last Updated:	August 19, 2008
ClinicalTrials.gov Identifier:	NCT00415428
Health Authority:	Unkown:

Study placed in the following topic categories:

Metabolic Diseases

Heart Diseases

Diabetes Mellitus, Type 2

Diabetes Mellitus

Vascular Diseases

Endocrine System Diseases

Endocrinopathy

Metabolic disorder

Glucose Metabolism Disorders

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 17, 2008